Medtronic raises fiscal 2027 outlook for Medtronic stock

Published on 10/01/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock costs EUR 76.03 versus EUR 76.58 on October 1, 2026. Fiscal 2027 guidance now spans 7.25 percent to 7.75 percent.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 76.03 at Lang & Schwarz on October 1, 2026 at 11:03 a.m. CEST, while the company raised its fiscal 2027 organic revenue growth guidance to 7.25 percent to 7.75 percent from 6.75 percent to 7.25 percent on September 1, 2026. The move followed a fiscal 2027 first-quarter performance that exceeded expectations across several operating portfolios.

Guidance rose after a strong quarter

According to Medtronic on September 1, 2026, first-quarter revenue was USD 9.756 billion, an increase of 13.7 percent from USD 8.578 billion in the prior-year quarter. GAAP diluted earnings per share reached USD 1.14, while non-GAAP diluted earnings per share came to USD 1.45, up 15.1 percent year over year.

The revised outlook also lifted fiscal 2027 diluted non-GAAP earnings per share guidance to USD 5.94 to USD 6.00 from USD 5.90 to USD 6.00. The guidance change is material because it combines a higher revenue-growth range with a narrow earnings range, leaving execution and product mix central to the next update.

Analysts keep a higher target

As Investing.com reported on September 30, 2026, TD Cowen reiterated a Buy rating and maintained its USD 110.00 price target. The target stood 27.25 percent above the USD 86.56 price cited in that analyst report, using the same currency and reference price.

MarketBeat reported on September 15, 2026, that 19 of 28 tracked research firms rated Medtronic a Buy, while nine assigned a Hold rating. The average 12-month target was USD 103.92, giving the stock a quantified valuation reference alongside the more cautious target maintained by TD Cowen.

Next test arrives in November

Medtronic's next scheduled reporting event is November 24, 2026, according to Investing.com. The same report identifies a December 10 to December 11, 2026 Investor Day, where management is expected to provide more detail on portfolio growth, margins, robotics and capital allocation.

Medtronic stock trades below prior close

At Lang & Schwarz, Medtronic stock was trading at EUR 76.03 on October 1, 2026 at 11:03 a.m. CEST, down 0.72 percent versus the prior close of EUR 76.58. The primary listing is on the New York Stock Exchange, where the structured quote showed USD 86.29 at September 30, 2026 at 4:00 p.m. ET; its 52-week range was USD 73.31 to USD 106.33 and market capitalization was USD 110.5 billion.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.